Pregabalin: a new anxiolytic

@article{LauriaHorner2003PregabalinAN,
  title={Pregabalin: a new anxiolytic},
  author={Bianca Lauria-Horner and Robert B Pohl},
  journal={Expert Opinion on Investigational Drugs},
  year={2003},
  volume={12},
  pages={663 - 672}
}
Pregabalin (S-[+]-3-isobutylgaba) was designed as a lipophilic GABA (γ-aminobutyric acid) analogue substituted at the 3′-position in order to facilitate diffusion across the blood–brain barrier. It was originally developed as an anticonvulsant agent, however it has been shown to be effective in the treatment of several disorders including hyperalgesia and behavioural disorders. Although its exact mode of action remains unclear, pregabalin interacts with the same binding site and has a similar… Expand
Pregabalin Pharmacology and Its Relevance to Clinical Practice
TLDR
Pregabalin is a potent ligand for the alpha‐2‐delta subunit of voltage‐gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models and is unlikely to cause, or be subject to, pharmacokinetic drug–drug interactions. Expand
Pregabalin: in the treatment of generalised anxiety disorder.
TLDR
Oral pregabalin, typically at dosages of 300-600 mg/day, was superior to placebo and similar to lorazepam, alprazolam and venlafaxine in improving anxiety and depressive symptoms in patients with moderate-to-severe generalised anxiety disorder (GAD). Expand
Pregabalin Abuse and Addiction
Abstract Pregabalin, and its structurally related compound gabapentin, are known as α2δ ligands due to their interaction with the calcium (Ca2+) channel α2δ subunit. They may act as inhibitoryExpand
Pregabalin: in the treatment of postherpetic neuralgia.
TLDR
Oral pregabalin 150-600 mg/day, administered in two or three divided doses, was significantly more effective than placebo in relieving pain and improving pain-related sleep interference in four randomized, double-blind, multicentre studies of 4-13 weeks' duration in patients with postherpetic neuralgia (PHN). Expand
Pregabalin: in the treatment of painful diabetic peripheral neuropathy.
TLDR
Oral pregabalin at fixed dosages of 300 and 600 mg/day, administered three times daily, was superior to placebo in relieving pain and improving pain-related sleep interference in three randomised, double-blind, multicentre studies of 5-8 weeks' duration in a total of 724 evaluable patients with painful diabetic peripheral neuropathy (DPN). Expand
Pregabalin: in the treatment of postherpetic neuralgia.
TLDR
Oral pregabalin 150-600 mg/day, administered twice or three times daily, was superior to placebo in relieving pain and improving pain-related sleep interference in three randomised, double-blind, placebo-controlled, multicentre studies of 8-13 weeks' duration in a total of 776 evaluable patients with postherpetic neuralgia (PHN). Expand
Pregabalin: Its Pharmacology and Use in Pain Management
  • N. Gajraj
  • Medicine
  • Anesthesia and analgesia
  • 2007
TLDR
The pharmacology of pregabalin is discussed, which results in a reduction in the release of several neurotransmitters, including glutamate, noradrenaline, serotonin, dopamine, and substance P. Expand
The effect of pregabalin and gabapentin on preoperative anxiety and sedation: a double blind study
TLDR
Preoperative pregabalin and gabapentin administration 1 hour before surgery led to significant reduction in preoperative anxiety and improves sedation without producing significant side effects. Expand
Further potential of the GABA receptor in the treatment of insomnia
Abstract The benzodiazepine binding site on the GABA A receptor is the target for the majority of hypnotics, including the nonbenzodiazepine ‘Z drugs' (zaleplon, zolpidem, zopiclone and eszopiclone).Expand
Pregabalin for Pain Management
  • N. Gajraj
  • Medicine
  • Pain practice : the official journal of World Institute of Pain
  • 2005
TLDR
Pregabalin is a new analog of the neurotransmitter gamma‐aminobutyric acid (GABA) that has analgesic, anticonvulsant, and anxiolytic activity and binds potently to the α2‐δ subunit resulting in modulation of calcium channels and reduction in the release of several neurotransmitters. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 97 REFERENCES
Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
TLDR
Data indicate that pregabalin may possess clinical utility as a novel anxiolytic agent and demonstrates the importance of the α2δ subunit of VDCC in the mediation of anxiety related behaviours. Expand
3‐Substituted GABA analogs with central nervous system activity: A review
TLDR
Pregabalin was identified after an investigation into other 3‐substituted GABA analogs and has since been shown to have a similar pharmacological profile to gabapentin with greater potency in preclinical models of pain and epilepsy. Expand
Upregulation of γ-aminobutyric acid transporter expression: role of alkylated γ-aminobutyric acid derivatives
Pregabalin [( S )-(+)-3-isobutylgaba] and gabapentin [1-(aminomethyl)cyclohexane acetic acid] are γ-aminobutyric acid (GABA) derivatives that are effective in the treatment of behavioural disorders,Expand
The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the Subunit of a Calcium Channel (*)
TLDR
[3H]Gabapentin is the first pharmacological agent described that interacts with an α subunit of a voltage-dependent Ca channel, and binding activity closely followed the elution of the α sub unit. Expand
Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies.
TLDR
Evidence is provided for the existence in brain of a novel binding site that may mediate the anticonVulsant effects of gabapentin and other potential anticonvulsant compounds. Expand
Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agents
TLDR
The present study evaluates the activity of gabapentin and the two enantiomers of 3‐isobutylgaba in formalin and carrageenan‐induced inflammatory pain models and found that the morphine tolerance did not cross generalize to gABapentin. Expand
A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin Is the Underlying Cause of the Lack of Proportionality Between Increasing Dose and Drug Levels in Plasma
TLDR
These findings support absorption of gabapentin by a saturable pathway, system L, shared by the large hydrophobic amino acids, L-Phe and L-Leu, made a major contribution to the lack of proportionality in plasma levels of drug with increasing dose ob-served in the clinic. Expand
Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain.
TLDR
It is suggested that gabapentin and S-(+)-3-isobutylgaba may be effective in the treatment of postoperative pain. Expand
The New Generation of GABA Enhancers
TLDR
Ganaxolone, retigabine and pregabalin may prove to have a more advantageous therapeutic profile than the presently licensed GABA enhancing drugs, and CGP 36742, a GABAb receptor antagonist, may be particularly useful in the management of primary generalised absence seizures. Expand
Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies.
TLDR
The results of experiments using [3H]gabapentin with homogenates of rat brain show the discrete localization of this novel binding site in regions associated with excitatory amino acid input and do not support previous indications of an association of the gabapents binding site and NMDA/glycine receptor complex. Expand
...
1
2
3
4
5
...